Precision Therapeutics Inc (NASDAQ:POAI) was the recipient of a significant growth in short interest in November. As of November 29th, there was short interest totalling 69,900 shares, a growth of 12.7% from the November 14th total of 62,000 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average trading volume of 24,700 shares, the short-interest ratio is currently 2.8 days.
A hedge fund recently bought a new stake in Precision Therapeutics stock. Vanguard Group Inc. purchased a new stake in Precision Therapeutics Inc (NASDAQ:POAI) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 155,934 shares of the medical instruments supplier’s stock, valued at approximately $115,000. Vanguard Group Inc. owned approximately 0.51% of Precision Therapeutics at the end of the most recent reporting period. 10.89% of the stock is owned by hedge funds and other institutional investors.
Separately, ValuEngine raised shares of Precision Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd.
POAI remained flat at $$2.72 during trading on Friday. 62 shares of the company traded hands, compared to its average volume of 39,812. The stock has a fifty day moving average price of $3.24. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.02. Precision Therapeutics has a 1 year low of $2.35 and a 1 year high of $11.50.
About Precision Therapeutics
Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.
Featured Story: Using the New Google Finance Tool
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.